Market Place
Sourcing Support
Verastem Complete NDA Submission for Avutometinib in Ovarian Cancer
31 Oct 2024 //
BUSINESSWIRE
Verastem Announces RAMP 201 Data Oral Presentation At IGCS 2024
09 Oct 2024 //
BUSINESSWIRE
Verastem Receives FDA Orphan Drug Designation For Pancreatic Cancer
29 Jul 2024 //
BUSINESSWIRE
ASCO: Verastem’s combo therapy for pancreatic cancer hits early trial success
25 May 2024 //
CLINICALTRIALSARENA
Verastem Receives Orphan Drug Designation from FDA for Avutometinib Alone
05 Mar 2024 //
BUSINESSWIRE
Verastem Oncology Outlines Key 2024 Strategic Priorities
29 Jan 2024 //
BUSINESSWIRE
Verastem Granted Fast Track Designation for Avutometinib and Sotorasib
18 Jan 2024 //
BUSINESSWIRE
Verastem Announces Initiation of a Confirmatory Phase 3 Trial of Avutometinib
13 Dec 2023 //
BUSINESSWIRE
Verastem Oncology Announces Efficacy and Safety Data of Avutometinib
06 Nov 2023 //
BUSINESSWIRE
Verastem Announces Results of RAMP 203 Trial of Avutometinib and LUMAKRAS
14 Oct 2023 //
BUSINESSWIRE
Verastem Presents Avutometinib and Defactinib Combination Program Updates
28 Sep 2023 //
BUSINESSWIRE
Verastem Oncology Announces Design for Trial of Avutometinib and Defactinib
05 Jul 2023 //
BUSINESSWIRE
Avutometinib/Defactinib Combo Generates Early Efficacy Signals in Ovarian Cancer
30 Jun 2023 //
ONCLIVE
New Data from Interim Analysis of Verastem Oncology’s RAMP 201 Trial
26 Apr 2023 //
BUSINESSWIRE
Verastem Presents Updated PI/II Data of VS-6766 + Defactinib in Ovarian Cancer
19 Sep 2021 //
BUSINESSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.